DCG-IV

DCG-IV
(IUPAC) ime
(1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina
Klinički podaci
Identifikatori
CAS broj 147782-19-2
ATC kod nije dodeljen
PubChem[1][2] 5310979
Hemijski podaci
Formula C7H9NO6 
Mol. masa 203,149 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3).[3] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.[4][5][6][7] On isto tako pokazuje antiparkinsonove efekte,[8][9] mada je poznato da usporava formiranje memorija.[10][11]

Reference

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (August 1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology 109 (4): 1169–77. PMC 2175774. PMID 8401927. 
  4. ↑ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology 256 (1): 109–12. DOI:10.1016/0014-2999(94)90624-6. PMID 7517889. 
  5. ↑ Yoshioka H, Sugita M, Kinouchi H (September 2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters 461 (3): 266–70. DOI:10.1016/j.neulet.2009.06.056. PMID 19549561. 
  6. ↑ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research 805 (1-2): 138–43. DOI:10.1016/S0006-8993(98)00698-2. PMID 9733953. 
  7. ↑ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience 13 (10): 1023–7. DOI:10.1016/j.jocn.2005.11.042. PMID 17113985. 
  8. ↑ Dawson L, Chadha A, Megalou M, Duty S (February 2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology 129 (3): 541–6. DOI:10.1038/sj.bjp.0703105. PMC 1571875. PMID 10711353. 
  9. ↑ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience 113 (4): 857–69. DOI:10.1016/S0306-4522(02)00232-4. PMID 12182892. 
  10. ↑ Huang LQ, Rowan MJ, Anwyl R (February 1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport 8 (3): 687–93. DOI:10.1097/00001756-199702100-00022. PMID 9106748. 
  11. ↑ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior 80 (5): 747–58. DOI:10.1016/j.physbeh.2003.12.010. PMID 14984810. 

Vanjske veze

Portal Medicina
Portal Hemija